We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Immunitybio, Inc. (NASDAQ:IBRX) stands against other firms that took a hit on ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

BTIG Research began coverage on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $6.00 price target on ...

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA ...

Shares of ImmunityBio (NASDAQ:IBRX) were up 15% in midday trading Thursday, the day after it issued updates on its regulatory submissions in the United States, European Union and United Kingdom.

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other top small cap stocks to buy with the highest upside potential. On December 30 ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...